- Login
- Register & Subscribe
- Langue: EN FR DE
Research & University News
Ipsen and Salk Institute renew research agreement
Tuesday 12 July 2011
Ipsen SA and The Salk Institute for Biological Studies of the US are renewing for another three years, their research collaboration to explore the biology of proliferative and degenerative diseases. Financial details were not disclosed.
Location
France
SuppreMol to test protein in lupus
Monday 11 July 2011
Venture-capital backed SuppreMol GmbH has announced the start of a Phase 2a study of a recombinant protein for systemic lupus erythematosus. This follows FDA approval in March of an antibody therapeutic for lupus from GSK, the first new drug for the disease since 1955.
Location
Germany
Novel antibody against influenza reported
Friday 8 July 2011
A novel monoclonal antibody that is said to have the potential to neutralise most group 2 influenza A viruses has been described in a paper in the journal Science. The research was conducted by Crucell NV and The Scripps Research Institute of the US.
Location
Netherlands
Sanofi stops Multaq trial in AF
Thursday 7 July 2011
Sanofi SA has stopped a Phase 3b trial of its antiarrhythmic, Multaq (dronedarone), in patients with permanent atrial fibrillation following a significant increase in cardiovascular events in those receiving the drug.
Location
France
Study suggests new targeted approach for MS
Tuesday 5 July 2011
A study published in Nature Medicine has suggested that inhibiting a receptor called death receptor-6 may represent a novel approach for the treatment of multiple sclerosis. The study was undertaken by researchers at Biogen Idec of the US.
Location
United States
Novartis says Afinitor study stopped early
Tuesday 5 July 2011
Novartis AG said that its Phase 3 trial of Afinitor (everolimus) for women with advanced breast cancer has been stopped early after interim results showed that the primary endpoint of progression-free survival was met.
Location
Switzerland
AstraZeneca to license new discovery technology
Monday 4 July 2011
AstraZeneca Plc is to make an undisclosed up-front cash payment to PTC Therapeutics Inc for access to technology that regulates the rate and timing of protein production in the cell. The goal is to discover new small molecule drugs for cancer.
Location
United Kingdom
Neurotoxic effects of pollutants to be studied
Friday 1 July 2011
A project aimed at developing tools to monitor the neurotoxic effects of environmental pollutants on developmental disorders in children has been funded by the European Commission under its 7th Framework programme for research.
Location
United Kingdom
Oxford BioMedica reports on gene therapy
Wednesday 22 June 2011
Oxford BioMedica Plc said that its gene therapy for wet age-related macular degeneration was shown to be safe and well-tolerated following the administration of a first dose in a Phase 1 study at the Wilmer Eye Institute at Johns Hopkins Hospital in the US.
Location
United Kingdom
Roche reports on vismodegib for basal cell carcinoma
Monday 20 June 2011
Roche has reported that its investigational treatment for advanced basal cell carcinoma, vismodegib, shrank tumours in a Phase 2 study of patients with locally-advanced disease and those with metastatic disease.
Location
Switzerland
Select a News Category
Recent Appointments
Steffen Thirstrup joins NDA Group
Monday June 10 2013
Tarquin Bennett-Coles joins Odgers Berndtson
Monday June 10 2013
Sandy Eisen becomes non-executive director at Phosphate Therapeutics
Thursday June 6 2013
Eric-Paul Paques to chair Grünenthal
Thursday June 6 2013
Charles DeCarli joins advisory board at DiaGenic
Thursday June 6 2013